Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on September 12, 2018, reporting events that occurred on September 11, 2018. The filing details the entry into material definitive agreements involving the issuance of convertible promissory notes and warrants to raise capital for working capital and general corporate purposes.
Key Financial Metrics and Transaction Details
The Company entered into two Note Purchase Agreements to raise a total of $500,000 in cash proceeds:
- L2 Capital Transaction: Issued a convertible note with a principal amount of $455,000 for a purchase price of $400,000. This includes a $45,000 original issue discount and $10,000 added to the principal to cover legal fees.
- Investor Transaction: Issued a convertible note to an accredited investor (brother of the CEO) with a principal amount of $111,250 for a purchase price of $100,000. This includes an $11,250 original issue discount.
- Interest Rate: 8% per annum.
- Maturity Date: March 11, 2019.
- Conversion Price: $0.85 per share if not repaid by maturity.
Equity Inducements:
- L2 Capital received 75,000 immediate shares and a 5-year warrant to purchase 185,417 shares at $0.90 per share.
- The Investor received a 5-year warrant to purchase 33,918 shares at $1.23 per share.
Material Changes and Covenants
The filing represents a material change in the Company's capital structure and debt obligations. Key restrictive covenants include:
- Use of Proceeds: The Company must use 100% of any outside funds received (excluding product sales revenue) to repay the Notes.
- Issuance Restrictions: The Company is restricted from issuing securities convertible into Common Stock at a variable price without a floor within 50% of the current market price unless the Notes are repaid.
- Exchange Cap: Upon conversion, neither holder may own more than 19.99% of the Company's outstanding Common Stock without shareholder approval.
- Redemption Rights: The Company may redeem the Notes at a premium ranging from 102.5% to 125% of the outstanding balance depending on the timing of redemption.
Outlook, Risks, and Contingencies
Default Provisions: In the event of default, the noteholders have the right to redeem the Notes at 135% of the outstanding balance, with an additional 5% penalty for each default. Interest accrues at 1.5% per month (18% annual) following a default.
Registration Rights: The Company agreed to file a registration statement for the resale of the shares within 120 days and use reasonable best efforts to have it declared effective within 180 days.
Related Party Transaction: One of the investors is the brother of the Company's Chief Executive Officer, Lisa A. Conte.
Investor Verification Checklist
- Verify the Company's current cash position and ability to repay the $566,250 total principal balance by March 11, 2019.
- Assess the dilution impact of the 75,000 immediate shares and the potential conversion of notes and exercise of warrants.
- Review the "Use of Proceeds" covenant to understand restrictions on future fundraising outside of product sales.
- Confirm the status of the registration statement filing required within 120 days of September 11, 2018.
- Monitor for any events of default that could trigger the 18% annual penalty interest rate.